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Type 2 diabetes is a genetically heterogeneous disease, with several relatively rare monogenic forms and
a number of more common forms resulting from a complex interaction of genetic and environmental factors.
Previous studies using a candidate gene approach, family linkage studies, and gene expression profiling un-
covered a number of type 2 genes, but the genetic basis of common type 2 diabetes remained unknown. Re-
cently, a new window has opened on defining potential type 2 diabetes genes through genome-wide SNP
association studies of very large populations of individuals with diabetes. This review explores the pathway
leading to discovery of these genetic effects, the impact of these genetic loci on diabetes risk, the potential
mechanisms of action of the genes to alter glucose homeostasis, and the limitations of these studies in
defining the role of genetics in this important disease.We are in the midst of a worldwide epidemic of type 2 diabetes,
obesity, and metabolic syndrome—each created by complex in-
teractions between genes and environment. For decades, inves-
tigators have worked to unravel the role of genetics in type 2 di-
abetes through epidemiological studies, studies of candidate
genes, and genetic linkage in families. While this has provided
important insights into some rare monogenic forms of diabetes,
understanding the genetics of common type 2 diabetes remains
a major challenge. Over the past year, a number of exciting arti-
cles have been published based on high-throughput genome-
wide association (GWA) studies. These have not only uncovered
a number of new genetic loci associated with diabetes and pro-
vided new targets for mechanistic investigation, but are also
forcing us to reconsider the degree of genetic heterogeneity
and possibly even the role of genetics itself in the pathogenesis
of type 2 diabetes. In this Review, we reconstruct the events that
led to this major paradigm shift, review the findings emerging
from these studies, and discuss the potential implications and
limitations of these discoveries for understanding the basic path-
ophysiology, as well as prediction, prevention, and treatment of
type 2 diabetes.
Type 2 Diabetes: A Major Public Health Problem Arising
from Environmental and Genetic Exposures
More than 20 million Americans and over 170 million individuals
worldwide suffer from diabetes mellitus (Hogan et al., 2003).
Despite advances in treatment, diabetes is the leading cause of
chronic renal failure, adult blindness, and limb amputation, and
a major risk factor for heart disease, stroke, and birth defects (Kro-
lewski and Warram, 2005). As a result, the cost of diabetes care in
the U.S.currently exceeds$200billionannually, representing over
12% of all health-care dollars. These staggering human and eco-
nomic costs will increase further as the prevalence of diabetes is
expected to double worldwide by 2025 (Cowie et al., 2006).
By far, the largest proportion of this public health problem de-
rives from type 2 diabetes, which accounts for more than 90% of
diabetes in the US and worldwide (Skyler and Oddo, 2002). Un-
like type 1 diabetes, which is caused by insulin deficiency due to186 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.autoimmune destruction of pancreatic b cells, type 2 diabetes
arises from an impairment in the ability of muscle, fat, and liver
to respond to insulin, i.e., insulin resistance, combined with an in-
ability of the b cell to respond normally to glucose by appropri-
ately increasing insulin secretion (Kahn, 1994). While the relative
contribution of these two defects to diabetes pathogenesis con-
tinues to be debated, longitudinal studies in high-risk individuals
suggest that insulin resistance is an early phenomenon, occur-
ring years before any evidence of glucose intolerance, whereas
the b cell failure develops later in the pathogenesis of disease
(Martin et al., 1992). On the other hand, other studies have shown
that the disposition index, reflecting both insulin sensitivity and
insulin secretion, is an early marker of and predictor of type 2
diabetes (Lyssenko et al., 2005; Bergman, 2007).
Both insulin resistance and b cell failure are thought to result
from the complex interplay of many different pathways under
the combined control of environmental and genetic factors (Fig-
ure 1). The role of genetics in type 2 diabetes (T2D) is indicated
by the familial clustering of insulin sensitivity and insulin secre-
tion, the higher concordance rate of T2D in monozygotic versus
dizygotic twins, and the high prevalence of type 2 diabetes in
certain ethnic groups (e.g., Pima Indians or Mexican Americans)
(Weijnen et al., 2002; Flegal et al., 1991). It has been estimated
that 30%–70% of T2D risk can be attributed to genetics (Poulsen
et al., 1999). Patterns of inheritance suggest that type 2 diabetes
is both polygenic and heterogeneous—i.e., multiple genes are
involved and different combinations of genes play a role in differ-
ent subsets of individuals. Exactly how many genes and what
their relative contributions are, however, remains uncertain,
with some investigators postulating that type 2 diabetes consists
of two or three major types with some minor types (Rich, 1990;
Kahn et al., 1996).
The Search for Type 2 Diabetes Genes in the
Pre-Genome-wide Association (GWA) Era
Over the past two decades four approaches have been used to
unravel the genetics of type 2 diabetes, each with some success
(Table 1). The first approach was to focus on forms of type 2
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itance and/or other specific clinical features. This led to the dis-
covery of genes involved in maturity onset diabetes of the young
(MODY); the genes involved in several syndromes of severe insu-
lin resistance (the type A syndrome, leprechaunism, Rabson-
Mendenhall syndrome, and lipoatrophic diabetes); the genes
involved in neonatal diabetes; and the genes involved in mito-
chondrial diabetes and other rare genetic syndromes (Table 2).
Together, these monogenic forms of type 2 diabetes account
for less than 2%–5% of this disease. Defining these relatively
rare diabetes genes, however, has provided novel insights into
pathways involved in the regulation of glucose homeostasis.
For instance, elucidating the family of MODY genes has high-
lighted a complex hierarchical network of transcription factors
modulating b cell development and function (Duncan et al.,
1998). Similarly, the discovery of mutations in the insulin recep-
tor, Akt2, and PPARg in syndromes of severe insulin resistance
confirms the important role of these signaling proteins in vivo
in humans (O’Rahilly, 2007). From a therapeutic perspective,
the identification of mutations in the ATP-sensitive potassium
channel (Kir6.2/KCNJ11) in infants with neonatal diabetes has
been very important, allowing these children to be treated with
oral sulfonylureas rather than lifelong insulin injections (Gloyn
et al., 2004; Pearson et al., 2006). More interesting from a mech-
anistic perspective has been the discovery of mutations in genes
not previously linked to diabetes, such as the genes for the
nuclear membrane protein lamin A or the protein seipin
(BSCL2) in certain forms of lipodystrophy and insulin resistance
(Shackleton et al., 2000; Magre et al., 2001). However, exactly
how mutations in these genes result in either lipodystrophy or
severe insulin resistance remains unclear.
The second approach to identify diabetes genes has been to
search for genetic variants in candidate genes that might be asso-
ciated, i.e., more frequent, in individuals with common type 2 di-
abetes (Hansen and Pedersen, 2005). In general, these studies
have focused on functional candidate genes—i.e., genes whose
products are known to play a role in glucose homeostasis, or po-
sitional candidate genes—i.e., genes located in chromosomal re-
gions that had been identified in linkage studies. By focusing on
Figure 1. Complex Pathogenesis of Type 2 Diabetes
Genetic and environemntal factors may influence the risk of diabetes through
the pathways ilustrated in the figure or through as-yet-unidentifed mecha-
nisms affecting insulin sensitivity and/or insulin secretion.genes already implicated in glucose homeostasis, the functional
candidate gene approach is geared toward confirming the role
of genes in diabetes rather than discovering as-yet-unknown
disease pathways. The positional candidate gene strategy
has more potential for discovery of new genes; however, this
approach is limited by the low sensitivity of linkagestudies for mul-
tifactorial disorders and the large size of linked genetic intervals.
Despite these shortcomings, these approaches have had some
success. Candidate gene studies led to the identification of
a common amino acid substitution in the nuclear receptor and
adipogenic transcription factor PPARg (Pro12Ala, rs1801282),
which has a modest, yet extensively replicated effect on the risk
of type 2 diabetes (Beamer et al., 1998). Similarly, the diabe-
tes-associated Glu23Lys variant was identified in the KCNJ11
gene, which encodes Kir6.2, one of the two components of the
KATP channel essential for normal glucose-stimulated insulin se-
cretion (Barroso et al., 2003). Functionally significant polymor-
phisms have also been identified in proteins involved in insulin
action, including a ‘‘gain-of-function’’ polymorphism (K121Q) in
the insulin action inhibitor ENPP1 (Pizzuti et al., 1999), the insulin
receptor substrates IRS1 and IRS2 and phosphatidylinositol 3-
kinase (Almind et al., 1996; Almind et al., 2002). Some, but not
all, of these associations with T2 DM have been confirmed by
meta-analysis or studies in large, diverse populations (McAteer
et al., 2008; Florez et al., 2004a). Positional candidate efforts,
on the other hand, have been mostly inconclusive, despite iden-
tification of multiple genomic regions linked to diabetes (e.g., 1q,
20q) (Stern, 2002). One notable exception is the identification of
TCF7L2 as a type 2 diabetes gene (discussed below) (Grant
et al., 2006).
Table 1. Identifying the Genes for Type 2 Diabetes
Studies of Monogenic Forms of Type 2 Diabetes
Maturity Onset Diabetes of the Young (MODY)
Rare forms of severe insulin resistance
Neonatal diabetes
Mitochondrial syndromes of diabetes
Candidate Gene Approach
Functional
Genes involved in insulin action and insulin secretion
Genes associated with diseases associated with diabetes
(obesity, genetic syndromes, etc)
Genes identified in animal models of diabetes
Positional
Genes in linked intervals identified through family studies
Useful for monogenic forms of diabetes (e.g., MODY)
Challenging for common, multifactorial Type 2 diabetes
Finding Genes with Altered Levels of Expression
Subtraction cloning and differential display
Microarray analysis (gene expression arrays)
Genome-wide Association Studies
Microarray-based typing ofR 100K SNPs spanning the entire
genome
Large populations of diabetic cases and non-diabetic controls
Populations with intermediate phenotypes – obesity,
insulin resistance, polycystic ovarian diseaseCell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc. 187
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Gene Name Common/Other Name Cellular Function
Chromosome
Location
OMIM
Number Diabetes Phenotype
Monogenic Causes of b Cell Dysfunction
MODY Diabetes
HNF4A HNF4alpha Transcription factor 20q12 600281 MODY1; b-cell dysfunction
GCK Glucokinase Glucose phosphorylation 7p15 138079 MODY2; mild life-long fasting
hyperglycemia
TCF1 HNF1alpha Transcription factor 12q24 142410 MODY3; progressive b-cell
dysfunction
PDX1 Insulin promoter
factor 1 (IPF1)
Homeodomain transcription
factor
13q12 600733 MODY4: Heterozygote: similar
to HNF1A (rare); homozygote:
pancreatic agenesis and
neonatal diabetes
TCF2 HNF1beta Transcription factor 17q21 189907 MODY5; Renal cysts and diabetes,
pancreatic atrophy, neonatal diabetes
NEUROD1 Beta2 bHLH Transcription factor 2q32 601724 MODY6; Similar to HNF1A (rare)
KLF11 Kruppel-like factor 11 TGF-beta inducible
Transcription Factor
2p25 610508 MODY7; impairs activation
of insulin promoter
CEL Carboxyl-ester lipase Lipid metabolism 9q34.3 114840 MODY8; Exocrine and b-cell
dysfunction (rare)
Neonatal Diabetes
KCNJ11 Kir6.2 Potassium channel 11p15.1 600937 Permanent and transient
neonatal diabetes
ABCC8 Sur1 Sulfonylurea receptor 11p15.1 600509 Permanent and transient
neonatal diabetes
EIF2AK3 PERK Pancreatic eIF2-alpha kinase 2p12 604032 Wolcott-Rallison Syndrome
PLAGL1 Pleomorhpic adenoma
gene 1; hydatidiform
mole transcript
Plagl1 - Nuclear zinc finger
protein
6p24 606546 Imprinted region, exact gene
unclear; transient neonatal
diabetes type 1
HYMA1 603044
PTF1A Pancreas transcription
factor 1
Alpha subunit of PTF1 10p12 607194 Permanent neonatal diabetes
with cerebellar agenesis
INS Insulin Hormone 11p15.5 176730 Mutation in insulin, proinsulin,
and proinsulin processing
Mitochondrial Diabetes
Mitochondrial
genome
MIDD tRNA for leucine Mutation at
3243 mtDNA
590050 Maternally inherited diabetes
and deafness; other mitochondrial
mutation also observed
Mitochondrial
genome
Mitochondrial myopathy,
lipid type
tRNA for glutamic acid Mutation at
14709 mtDNA
500002 Mitochondrial myopathy
with diabetes
Other
WFS1 Wolframin 10 transmembrane domain
protein, function unknown
4p16.1 2223000 Diabetes insipidus and mellitus
with optic atrophy and deafness;
DIDMOAD; Wolfram Syndrome
ZCD2 ERIS Zinc finger protein ZCD2 4q22-q24 604928 Wolfram Syndrome 2
Monogenic Causes of Insulin Resistance
Severe Insulin Resistance
INSR Insulin receptor Receptor tyrosine kinase 19p13 147670 Insulin-resistant diabetes with various
phenotypes: leprechaunism, Rabson-
Mendenhall or type A syndrome
AKT2 PKB-beta Serine-threonine kinase 19q1 164731 Severe insulin resistance
Lipoatrophic Forms of Diabetes
LMNA Lamin A/C Inner nuclear membrane
protein
1q21 150330 Face-sparing partial lipodystrophy
with peripheral fat loss; mutations
also associated with cardiomyopathy;
muscular dystrophy; and
Hutchinson-Gilford Progeria188 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.
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Gene Name Common/Other Name Cellular Function
Chromosome
Location
OMIM
Number Diabetes Phenotype
LMNB2 Lamin B2 Inner nuclear membrane
protein
19p13 150341 Partial lipodystrophy sparing legs
(Barraquer-Simon Syndrome)
AGPAT2 1-acylglycerol-3-phosphophate
O-acyltransferase 2
Enzyme of phospholipid
metabolism
9q34 603100 Congenital generalized
lipodystrophy with skeletal lytic
lesions (Bernardinelli-Seip
Syndrome)
BSCL2 Seipin 398 amino acid protein of
unknown function
11q13 606158 Congenital generalized lipodystrophy,
learning disabilities
PPARG Peroxisome proliferator
activated receptor g
Nuclear receptor for
prostaglands and
thiazolidine-diones
3p25 601487 Rare variants in ligand binding
domain associated with insulin
resistance, hypertension, buttock
lipodystrophyA number of recent efforts have used microarray gene expres-
sion analysis in attempt to define genetic alterations in type 2
diabetes. These have uncovered two important findings. One
is a defect in skeletal muscle of humans with T2D characterized
by a coordinated decrease in the expression of nuclear-encoded
genes involved in mitochondrial oxidative phosphorylation (Patti
et al., 2003; Mootha et al., 2003). This appears to be secondary
to reduced expression of the transcriptional coactivators PGC-
1a and PGC-1b. Similar changes in expression have been
observed in some cohorts of first-degree relatives of diabetic in-
dividuals, suggesting that these may be heritable traits (Patti
et al., 2003), but thus far no primary genetic defect has been
linked to these changes. Although polymorphisms in PGC-1
and epigenetic modification of complex subunits may contribute
to age-associated reductions in expression (Ling et al., 2004,
2007, Ronn et al., 2008), other studies have suggested that
this expression phenotype may be secondary, at least to some
extent, to poor physical fitness, obesity, intramyocellular lipid ac-
cumulation, or insulin resistance itself (Crunkhorn et al., 2007).
Furthermore, the role of these changes in diabetes pathogenesis
is uncertain, since an animal model with primary reduced mito-
chondrial oxidative phosphorylation in muscle shows increased,
rather than decreased, insulin sensitivity (Pospisilik et al., 2007).
A second potential type 2 gene was discovered via microarray
analysis is the transcription factor ARNT/Hif1b. This was identi-
fied using islets isolated from humans with type 2 diabetes and
was associated with altered expression of many other genes in
the b cell involved in glucose sensing, insulin signaling, and tran-
scriptional control (Gunton et al., 2005). Again, however, it is not
clear which, if any, of these changes represent primary defects
or are secondary to trans-acting genes or metabolic/environ-
mental factors.
The GWA Revolution
By 2006 it had become clear that identifying the major genes of
type 2 diabetes would require a paradigm shift. Such a shift was
made possible by several parallel developments. One was the
completion of the HapMap project aimed at characterizing the
genome-wide pattern of linkage disequilibrium (Frazer et al.,
2007). Linkage disequilibrium (LD) is a statistical association be-
tween alleles at separate but linked loci, usually resulting from
a particular ancestral haplotype being common in the populationstudied (Strachan and Read, 2003). This phenomenon causes
adjacent polymorphisms to be correlated to the point of being
strong proxies for each other. With linkage disequilibrium, there-
fore, it becomes possible to select a set of 300,000 to 1 million
single nucleotide polymorphisms (SNPs) that can represent
most of the 10 million common SNPs estimated to be present
in the human genome. Coupled with improved microarray tech-
nology allowing precise typing of a large number of polymor-
phisms and access to DNA from large cohorts of patients with di-
abetes, the possibility of large GWA studies of diabetes became
a reality.
It is important to keep in mind that the GWA approach is not
without its own limitations. First, in its current implementation,
it assumes that the genetic variants conferring susceptibility to
type 2 diabetes are common, i.e., have a frequency of R5% in
the population. While theoretical models support this assump-
tion, rare variants have been shown to contribute significantly
to the modulation of complex metabolic traits (Brunham et al.,
2006). Second, the GWA strategy poses significant challenges
in terms of study design and data interpretation. For example,
type 2 diabetes is an age-dependent disease, and, thus any pop-
ulation of controls will include many individuals who might later
develop diabetes. Third, given the hundreds of thousands of
comparisons performed in the analysis, a large number of poly-
morphisms can be significant at the p < 0.05 or p < 0.001 level by
chance alone. Thus, a much more stringent significance thresh-
old must be used (e.g., p < 2 3 107 for a 300K array), meaning
that a very large sample size is needed in order to preserve
power. This, in turn, creates a financial challenge. The final,
and perhaps most important, challenge is what to study. Type
2 diabetes is not only polygenic and heterogeneous, but also is
closely linked to other metabolic phenotypes and has a progres-
sive pathogenesis, starting with insulin resistance and b cell dys-
function progressing to clinical hyperglycemia (Figure 1). Since
there are no precise markers for defining stages in this progress,
GWA studies were forced to focus on cases with clinically de-
fined type 2 diabetes, adding elements of complexity to interpre-
tation of results.
The GWA Studies for Type 2 Diabetes Genes
By the late spring of 2007, the results of five independent GWA
screens for type 2 diabetes genes had been published (SladekCell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc. 189
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2007; Steinthorsdottir et al., 2007) (see Table S1 for characteris-
tics of each study), and these were followed by five smaller GWA
studies (Salonen et al., 2007; Rampersaud et al., 2007; Hayes
et al., 2007; Florez et al., 2007; Hanson et al., 2007). The five large
studies were all conducted using a two-stage strategy consisting
of a GWA screen in an initial cohort of unrelated cases and con-
trols followed by replication of the most significant findings in ad-
ditional sets. The screening and replication sets consisted pri-
marily of European Whites, with the exception of the Decode
study, which included groups of Chinese from Hong Kong and
West Africans (Table S1). Altogether, the screening sets included
more than 7,000 cases and 12,000 controls; the replication sets
consisted of about 20,000 cases and 26,000 controls. The
screening set of the McGill/Imperial College study stands out
from others for the relatively young age at diagnosis (average
45 years) and the low BMI (average 25.8) of the individuals
with diabetes, a focus hoping to increase the probability of de-
tecting genetic effects, while excluding genes related to the eti-
ology of obesity. In the other four large studies, the phenotype of
cases was closer to that of common type 2 diabetes, with aver-
age age at diagnosis in the sixth decade. In the DGI study, a large
proportion of controls were matched to cases by BMI, whereas
in the other studies, the BMI was lower in controls than cases by
two or three points, similar to what is observed in the corre-
sponding source populations. The GWA screens were based
on the Illumina 300K or Affymetrix 500K genotyping array, both
capturing about 80% of common variants present in the human
genome of Caucasian individuals.
While each GWA screen identified dozens of potential can-
didates, at least 15 loci emerged as being most consistently
associated with risk of type 2 diabetes across multiple studies
(Table 3). Three of these correspond to genes that had already
been implicated in type 2 diabetes (TCF7L2, KCNJ11, PPARG);
the other 12 represent new potential type 2 diabetes genes.
Given the large number of cases and controls, these associa-
tions are highly significant. However, these large p values should
not be confused with the magnitude of the genetic effect as
quantified by its odds ratio (OR), which in all cases is relatively
small (Table 3). Two other striking features of these studies
were that most of the genes identified would not be considered
typical candidate genes for type 2 diabetes, and in most cases
the variants associated with type 2 diabetes were in noncoding
regions of the gene, suggesting alterations in regulatory ele-
ments and gene expression rather than amino acid sequence.
The following is a brief summary of the evidence linking these
15 loci to type 2 diabetes and some thoughts about possible
mechanisms involved in their effects.
TCF7L2 (10q25)
The strongest association in all of the studies is with a region on
chromosome 10q25 located in a 92 kb linkage disequilibrium
(LD) block in the TCF7L2 gene. While the identification of this
type 2 diabetes locus predates the GWA era (Grant et al.,
2006), the association of the TCF7L2 locus with T2D is by far
the strongest and most consistent signal across the GWA stud-
ies. In a meta-analysis of the WTCCC, Fusion, and DGI studies,
the combined odds ratio of type 2 diabetes per copy of the ‘‘high-
risk’’ allele is 1.37 (95% confidence interval, 1.31–1.43), with
a combined p value of 1048 (Zeggini et al., 2007; Scott et al.,190 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.2007; Saxena et al., 2007). Individuals homozygous for the
high-risk allele have about a doubling of diabetes risk, or to put
it another way, about 12% of them will have type 2 diabetes
versus 9% of heterozygotes and 6% of noncarriers. The
predisposing effect seems to be more pronounced among lean
than obese individuals (Cauchi et al., 2008a; Watanabe et al.,
2007).
TCF7L2, also known as TCF-4 or b-catenin interacting protein,
is a high-mobility group box-containing transcription factor that
is involved in the WNT signaling pathway, acting as a nuclear
receptor for b-catenin (Yi et al., 2005; Prunier et al., 2004). Wnt
signaling is critical for cell proliferation and involved in many as-
pects of embryogenesis, including adipogenesis (Prestwich and
MacDougald, 2007), myogenesis (Cossu and Borello, 1999), and
pancreatic islet development (McLin et al., 2007). TCF7L2 acti-
vation induces a variety of genes, including those for intestinal
proglucagon and glucagon-like peptides-1 and -2 (Fehmann
et al., 1995). The association with type 2 diabetes involves a com-
mon haplotype spanning part of intron 3, exon 4, and part of
intron 4, but does not include any coding variants, suggesting
an effect on gene expression as the most likely explanation for
association with type 2 diabetes.
Clinically, carriers of the high-risk TCF7L2 genotype have re-
duced insulin secretion (Florez et al., 2006a), suggesting a possi-
ble role for TCF7L2 in the b cell dysfunction of type 2 diabetes.
Overexpression studies in b cells, however, have given conflict-
ing results, in one case showing a blunting of glucose-stimulated
insulin secretion (Lyssenko et al., 2007) and in another a benefi-
cial effect to protect islets from glucose- and cytokine-induced
apoptosis and impaired function (Shu et al., 2008). Other studies
suggest roles for TCF7L2 in T2D via control of the incretin axis,
hepatic glucose production, and adipocyte function (Lyssenko
et al., 2007; Cauchi et al., 2006). Actual expression data for
TCF7L2 in humans are limited. One report indicates that islets
from carriers of the risk genotypes have increased TCF7L2
mRNA compared to noncarriers (Lyssenko et al., 2007), but no
significant difference in TCF7L2 expression was observed in
islets or muscle in a study of unselected human T2D in the
Diabetes Genome Anatomy Project (DGAP) (http://www.
diabetesgenome.org) (Figure 2, bottom). TCF7L2 could exert
its effect in a variety of ways, since TCF7L2 is expressed at
high levels in a wide variety of tissues, including the hypothala-
mus (Figure 2, top).
SLC30A8 (8q24)
The next strongest SNP after those in TCF7L2 is in a 33kb LD
block within the coding region of SLC30A8, a zinc membrane
transporter (Zn-T8) that is highly expressed in pancreatic islets
(Figure 3, top) (Chimienti et al., 2004). This gene first emerged
as a type 2 diabetes locus in the McGill/Imperial study (Sladek
et al., 2007). Although this polymorphism ranked only 34th in
the screening GWA set with ORs of 1.18 and 1.53 for heterozy-
gotes and homozygotes, respectively, this was one of only
a handful of SNPs for which the association with type 2 diabetes
was confirmed in the replication sets. Replication was also ob-
tained in the Decode, WTCCC, Fusion, and DGI studies (Zeggini
et al., 2007; Scott et al., 2007; Saxena et al., 2007; Steinthorsdot-
tir et al., 2007).
Of all of the new potential type 2 diabetes genes, SLC30A8 is
one of the few involving a nonsynonymous polymorphism—an
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Chromosome
Location
Gene
Symbol Common/Other name Cellular Function
OMIM
Number OR
Frequency of
Risk Allele
1p12 NOTCH2 Notch 2 preproprotein Regulator of cell
differentiation
600275 1.13 0.11
2p21 THADA Thyroid adenoma-
associated gene
Unknown 611800 1.15 0.90
3p14 ADAMTS9 Disintegrin-like and
metalloproteinase with
thrombospondin type 1
motif
Proteolytic enzyme
regulating extracellular
matrix
605421 1.09 0.76
3p25 PPARG Peroxisome proliferator
activating receptor gamma
(PPARg)
Transcription factor
receptor for TZDs and
prostaglandins
601487 1.17 0.85
3q28 IGF2BP2 IMP2 IGF2 mRNA-binding
protein 2
608289 1.14 0.29
6p22.3 CDKAL1 CDK5 regulatory subunit
associated protein 1-like 1
Presumed regulator of
cyclin kinase
611259 1.0-1.20 0.31
7p15 JAZF1 Juxtaposed with another
zinc finger gene 1
Zinc-finger protein of
unknown function
606246 1.10 0.50
8q24.11 SLC30A8 ZNT8 Zinc transporter 8 611145 1.18 0.65
9p21 CDKN2A
CDKN2B
p16 (INK4a) p14(ARF)p15
(INK4b)
Cyclin-dependent kinase
inhibitor 2A and 2B
600431 1.20 0.83
10p13-p14 CDC123 Cell division cycle protein
123 homolog
Required for S phase
entry of the cell cycle
- 1.11 0.18
CAMK1D Calcium/calmodulin-
dependent protein kinase
i-delta
Mediator of chemokine
signal transduction in
granulocytes
607957
10q23-q25 IDE Insulin degrading enzyme Neutral metallo-
peptidase that can
degrade many peptides
146680 1.13 0.53
HHEX Hematopoietically
expressed homeobox;
PRHX
Homeobox transcription
factor
604420
KIF11 Kinesin family member 11;
Homologue of Xenopus
EG-5
Kinesin related motor in
microtubule & spindle
function
148760
10q25.3 TCF7L2 TCF4 High mobility group
transcription factor
602228 1.31-1.71 0.26
11p15.1 KCNJ11 Kir6.2 Inwardly rectifying
potassium channel
600937 1.14 0.47
12q21 TSPAN8 Tetraspanin 8 Cell surface glycoprotein 600769 1.09 0.27
LGR5 Leucine-rich repeat-
containing G protein-
coupled
Orphan G protein-
receptor
606667
16q12.2 FTO Fat Mass- and Obesity-
Associated Gene
58kD protein with nuclear
localization signal
610966 1.27 0.38
OR = Odss ratio of type 2 diabetes per risk allele.arginine to tryptophan substitution at amino acid 325 (Sladek
et al., 2007). SLC30A8-overexpressing cells display enhanced
glucose-stimulated insulin secretion (Chimienti et al., 2006), sug-
gesting that the risk allele might act by impairing transporter
function, thereby decreasing the amount of zinc available for
cocrystallization with insulin in the secretory vesicles of b cells.
Reduced pancreatic and islet zinc levels have been observed
in some animal models of type 2 diabetes (Taylor, 2005), and
zinc supplementation has been shown to improve glucose toler-ance in db/db mice (Simon and Taylor, 2001). On the other hand,
studies have not identified any deficiency of pancreatic zinc
content in patients with type 2 diabetes (Taylor, 2005), and at
least one study suggests that dietary zinc supplementation in
humans with diabetes further decreased glucose tolerance
(Raz et al., 1989). Since zinc has many roles in the cell in addition
to its role in insulin crystallization, and since Zn-T8 is only one
member of a large family of zinc transporters, more mechanistic
studies are clearly warranted. SLC30A8 has also recently beenCell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc. 191
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et al., 2007).
HHEX/IDE/KIF11 (10q23)
A locus on 10q23 ranked third for association with T2D (after
TCF7L2 and SLC30A8) in the McGill scan, and was indepen-
dently replicated in the WTCCC, Fusion, and DGI studies giving
a small p value (p = 5.73 1010), but a combined OR of only 1.13.
SNPs at this locus have been also found to be associated with
measures of insulin secretion in a large multicentric study from
Europe and in the DPP study (Pascoe et al., 2007; Moore
et al., 2008). The association signal lies in a 295 Kb block of LD
that includes at least three potential type 2 diabetes genes:
HHEX (a homeobox transcription factor), KIF11 (a kinesin inter-
acting factor), and IDE (insulin degrading enzyme) genes (Table
3). Which, if any, of these genes actually contribute to type 2 di-
abetes risk is not known. Each of these genes shows rather
broad tissue expression (Figure 2, top). Based on its provocative
name and data suggesting roles in both insulin signaling and islet
function (Farris et al., 2003), IDEwould probably be viewed as the
strongest biological candidate gene at this locus. However,
a previous large study of IDE as a candidate for type 2 diabetes
Figure 2. Expression Profiles of Genes
Placed at the Type 2 Diabetes Loci
Identified to Date
(A) Expression levels across different tissues.
(B) Relative expression levels in skeletal muscle
and pancreatic islets from diabetic and nondia-
betic subjects. Skeletal muscle expression data
were derived from a cohort of metabolically char-
acterized Mexican-American subjects with estab-
lished DM2, treated with sulfonylureas or lifestyle
only (n = 5), and compared with control individuals
with normal glucose tolerance (n = 6) (Patti et al.,
2003). The data on pancreatic islets were derived
from isolated islets purified from five type 2 dia-
betic subjects and seven normoglycemic controls
(Gunton et al., 2005). The mean duration of type 2
diabetes was 5.8 ± 2.1 years, and no subjects
were insulin requiring. Mean HbA1c was 7.5 ±
0.5% in the diabetic subjects. RNA was extracted
from at least 1000 islet equivalents per subject.
RNA was prepared separately for each subject
and hybridized to Affymetrix U133A and B micro-
arrays. For each study, cRNA was prepared
separately for each subject and hybridized to
Affymetrix HuGene FL (muscle) and U133A and
B (islet) microarrays. Complete microarray data
sets are available on the Diabetes Genome
Anatomy Project (DGAP) website (http://www.
diabetesgenome.org).
was negative (Florez et al., 2006b). Rean-
alysis of the DGAP data reveals no differ-
ence in expression of IDE in islets be-
tween the individuals with diabetes and
healthy controls (Figure 2, bottom), while
in muscle, expression of IDE is modestly
reduced in T2 DM (21% decrease, p =
0.05). Despite its name, IDE is not an in-
sulin-specific protease and has been
shown to play roles in degradation of glu-
cagon, brain amyloid proteins, and viral
glycoproteins (Qiu et al., 1998). HHEX,
on the other hand, is a transcriptional repressor, active in cardiac
and pancreas development (Tanaka et al., 1999; Foley and Mer-
cola, 2005), as well as WNT signaling (McLin et al., 2007), while
KIF11 is involved in centrosome migration and mitosis (Kapitein
et al., 2005).
CDKAL1 (6p22)
An association signal at 6p22 maps to a 15 kb linkage disequi-
librium block in intron 5 of the gene for CDKAL1 (CDK5 regula-
tory subunit-associated protein 1-like 1). The strongest associa-
tion of 6p22 with T2D was observed in the Decode study (OR =
1.20) (Steinthorsdottir et al., 2007), with weaker association in
the WTCCC, Fusion, and DGI study (combined OR = 1.12),
and no association in the McGill/Imperial study (Sladek et al.,
2007; Zeggini et al., 2007; Scott et al., 2007; Saxena et al., 2007).
The CDKAL1 gene encodes a 65 kD protein that is expressed
in a broad range of tissues (Figure 2, top) and is believed to be an
inhibitor of CDK5 (cyclin-dependent kinase 5). CDK5 itself has
been shown to blunt insulin secretion in response to glucose
and to play a permissive role in the decrease of insulin gene ex-
pression that results from glucotoxicity (Ubeda et al., 2006).
Thus, one can speculate that reduced expression of CDKAL1192 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.
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would lead to decreased insulin secretion; in agreement, this lo-
cus was significantly associated with small decreases in insulin
response to a glucose load (Steinthorsdottir et al., 2007; Saxena
et al., 2007; Pascoe et al., 2007; Palmer et al., 2008, Stanca´kova´
et al., 2008). However, in the analysis of human islet and muscle
expression data from DGAP, there does not appear to be a sig-
nificant difference in the level of expression of CDKAL1 between
subjects with diabetes and controls (Figure 2, bottom).
CDKN2A/2B (9p21)
Two signals of association with T2D have been localized to
chromosome 9p21. The first one—represented by SNP
rs10811661—is supported by the DGI, WTCCC, and Fusion
scans with a combined OR of 1.20 and a p = 7.83 1015 (Zeggini
et al., 2007; Scott et al., 2007; Saxena et al., 2007). A second
weaker signal in this region was detected by the WTCCC and Fu-
sion studies about 100 kb in a telomeric direction (SNP rs564398,
p = 1.33 106 and p = 0.039, respectively). The two association
signals, involving noncoding polymorphisms, are separated by
a recombinationhotspotand thus could be independent.The cen-
tromeric signal (SNP rs10811661) is close to the CDKN2A and
CDKN2B genes (cyclin-dependent kinase inhibitor 2a and 2b)
and the telomeric signal includes both of these genes. Both genes
code for inhibitors of CDK4 (cyclin-dependent kinase 4).CDKN2A
encodes two molecules, p16INK4a and p14 (ARF), while CDKN2B
encodes p15INK4b (Kamb et al., 1994; Pomerantz et al., 1998).
CDK4 is involved in cell-cycle regulation in a wide variety of
cells. Interestingly, mice with targeted disruption of this gene
have small islets and develop insulin-deficient diabetes, while
mice expressing a CDK4 form insensitive to physiological inhib-
itors exhibit b cell hyperplasia (Rane et al., 1999). However,
a study of 1276 healthy individuals failed to observe any associ-
ation between CDKN2A or CDKN2B polymorphisms and insulin
secretion (Pascoe et al., 2007). These two genes, however, are
widely expressed and could have effects in many other tissues
(Figure 2, top). Furthermore, this region includes other genes, in-
cluding a mitochondrial RNA processing endoribonuclease and
the gene for methylthioadenosine phosphorylase (Nobori et al.,
1996), as well as several ESTs. Interestingly, a ‘‘major’’ locus
for coronary artery disease, abdominal aneurysms, and periph-
eral vascular disease has also been identified in this region
(Helgadottir et al., 2007; McPherson et al., 2007, Helgadottir
et al., 2008), suggesting a common genetic link between diabe-
tes and vascular disorders (Stern, 1995).
IGF2BP2 (3q27)
Association signals at 3q27 were observed in the WTCCC, Fu-
sion, and DGI scans, although the combined OR is only 1.14
(p = 8.93 1016) (Zeggini et al., 2007; Scott et al., 2007; Saxena
et al., 2007). This is consistent with previous studies showing
linkage at this location with quantitative metabolic traits and
type 2 diabetes (Kissebah et al., 2000; Vionnet et al., 2000).
The SNPs displaying the strongest association with type 2 diabe-
tes lie in a 50 kb region within intron 2 in the gene coding for IGF-
2BP2. IGF-2BP2 is not an IGF binding protein, but a protein that
binds to the 50UTR of the insulin-like growth factor 2 (IGF-2)
mRNA, thereby regulating its translation (Nielsen et al., 1999).
Several other genes with important metabolic functions are
also within the radius of a potentially regulatory effect by the
risk variants, including PPP1R2 (protein phosphatase 1, regula-tory subunit 2), MAP3K13 (mitogen-activated protein kinase ki-
nase kinase), LIPH (lipase H), DGKG (diacylglycerol kinase
gamma 1), AHSG (alpha-2-HS-glycoprotein, a putative inhibitor
of insulin receptor signaling), andADIPOQ, the insulin-sensitizing
adipokine adiponectin. Reanalysis of the DGAP human islet and
muscle data shows no difference in expression of IGF2BP2 in di-
abetes (Figure 2A), so whether the association with type 2 diabe-
tes is mediated by an effect on the expression of IGF2BP2 or
these other genes will have to be addressed by further studies.
FTO (16q12)
In the WTCCC scan, the association signal at this locus (OR =
1.27, p = 7.3 3 1014) was second in magnitude only to that of
TCF7L2 (Zeggini et al., 2007). The diabetes-associated alleles
at this location, however, were also strongly associated with in-
creased BMI, and the association with type 2 diabetes was lost
when the analysis was adjusted for body weight, suggesting that
the effect on T2D risk is mediated by an effect on adiposity. In-
deed, this locus has been associated with obesity, with ORs
ranging from 1.3 to 1.9 (Frayling et al., 2007; Dina et al., 2007).
Adults homozygous for the FTO risk allele weigh about 3 kg
more than individuals not carrying this allele. About 16% of white
Europeans are homozygous for the high-risk A allele, and these
individuals are 1.7 times more likely to be obese than those
homozygous for the low-risk T allele. The SNPs showing the
strongest association lie in a 47 kb linkage disequilibrium block
encompassing parts of the first two introns and exon 2 of the
FTO gene.
The function of the FTO (fat and obesity associated) gene is
still unclear. FTO shares sequence motifs with Fe(II)- and 2-oxo-
glutarate-dependent oxygenases and is localized in the nucleus,
where it catalyzes the demethylation of 3-methylthymine in sin-
gle-stranded DNA (Gerken et al., 2007). In mice FTO mRNA is
most abundant in the brain, particularly in hypothalamic nuclei
governing energy balance (Figure 2, top). FTO levels in the arcu-
ate nucleus are regulated by feeding and fasting (Gerken et al.,
2007). Other genes in close proximity to the FTO polymorphism
include an Akt interacting protein (AKTIP), two members of the
ATP binding cassette subfamily C (ABCC), and KIAA1005/
RPGRIP1L (a gene of unknown function). Functional studies
based on knockout and overexpression models will be needed
to understand the pathways through which variants at this locus
control body weight and glucose homeostasis.
KCNJ11 and PPARg
Most of the genes previously identified through the candidate
gene approach did not rank high for association with T2D in
the GWA studies. KCNJ11 and PPARG are two exceptions.
Both were found to be associated with type 2 diabetes in the
WTCCC, Fusion, and DGI studies with a combined OR of
1.14 (p = 6.7 3 1011 and p = 1.7 3 106, respectively) (Zeggini
et al., 2007; Scott et al., 2007; Saxena et al., 2007), and both
involve nonsynonymous polymorphisms. The association with
the KCNJ11 gene concerns a common glutamate to lysine sub-
stitution at position 23 (E23K). The lysine allele has been shown
to reduce the sensitivity of b cell ATP-sensitive K+ channels to-
ward inhibitory ATP4, thereby increasing the threshold for in-
sulin release (Schwanstecher et al., 2002). Consistent with
this, this polymorphism has been associated with an insulin se-
cretion defect in multiple studies (Nielsen et al., 2003, Florez
et al., 2004b). However, the b cell may not be the onlyCell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc. 193
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pressing a mutant Kir6.2 subunit (encoded by the KCNJ11
gene) in the hypothalamus driven by the POMC promoter ex-
hibits impaired whole-body glucose disposal and a defect in
glucose sensing in POMC neurons when placed on a high-fat
diet (Parton et al., 2007). Thus, the KCNJ11polymorphisms
could contribute to loss of glucose sensing in both the b cell
and POMC neurons, leading to impairment in insulin action,
as well as insulin secretion.
The identified polymorphism in PPARg, which appears to
modify susceptibility to type 2 diabetes mellitus and obesity,
was identified a decade ago and produces a Pro12-to-Ala
(P12A) change in the PPARg2 gene (Deeb et al., 1998; Beamer
et al., 1998). This was initially confirmed in a meta-analysis
(Altshuler et al., 2000) and reconfirmed in the GWA studies. Re-
sistance to diabetes is associated with the minor (Ala12) allele
and susceptibility with the major allele (Pro12), which has a prev-
alence of about 85% among nondiabetic individuals and 88%
among diabetic subjects. Exactly how this change in amino
acid produces this effect still remains unclear. However, this
change occurs specifically in the PPARg2 isoform of the gene,
which is the form specifically expressed in adipose tissue and
which is the target of the insulin sensitizing thiazolidinediones
(TZDs). Mutations in other functional regions of this gene have
also been found in individuals with severe insulin resistance
due to familial partial lipodystrophy type 3 (Barroso et al., 1999).
JAZF1, CDC123-CAMK1D, TSPAN8-LGR5, THADA,
ADAMTS9, and NOTCH2
Genomic loci near these six genes did not reach significance in
the original GWA screens, but their association with type 2 dia-
betes was confirmed in a large replication study including
more than 50,000 individuals, with OR ranging from 1.09 to
1.15 (Zeggini et al., 2008). JAZF1, CDC123/CAMK1D, and
TSPAN8-LGR5 are associated with small alterations in insulin
secretion, whereas the mechanisms linking the other three loci
to type 2 diabetes remain uncertain (Grarup et al., 2008).
Additional Loci Associated with
Quantitative Metabolic Traits
Mutations in the melanocortin-4 receptor (MC4R) have previ-
ously been shown to account for up to 5% of childhood-onset
severe obesity (O’Rahilly, 2007), and analysis of the GWAS
data has shown a modest, but consistent, association of fat
mass and waist circumference with a locus immediately down-
stream of this gene (Loos et al., 2008; Chambers et al., 2008).
Analysis of quantitative traits among the nondiabetic controls
of type 2 diabetes GWA studies has also identified variants in
the region of the glucose-6-phosphatase catalytic subunit 2
(G6PC2) that function as modulators of fasting glucose, although
this effect does not appear to translate into an increased risk of
type 2 diabetes (Chen et al., 2008). No consistent associations
have been thus far reported with measures of insulin secretion
and insulin sensitivity, but further insights are expected from
the meta-analyses of the available GWA data.
The Emerging Genetic Architecture of Type 2 Diabetes
Taken together, what do these GWA association studies tell us
about the genetics of type 2 diabetes? First, assuming our basic
model is correct, these studies suggest that type 2 diabetes may194 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.be more heterogeneous and more polygenic than previously be-
lieved. While previous reviews had suggested there may be two
or three major genetic forms of type 2 diabetes along with some
minor forms, the GWA studies would suggest that from a genetic
perspective type 2 diabetes represents a very large number of
different disorders. This seems a bit at odds with the common
clinical presentation of the disease and raises a question as to
how these different genetic forms of type 2 diabetes might differ
at a clinical level.
The second finding of these studies is the relatively high fre-
quency of each of the risk variants in the population, ranging
from 0.26 for TCF7L2 to 0.85 for PPARg (Table 3). The high fre-
quency of the risk variants together with the small risk of type 2
diabetes conferred by each allele translate into a very large num-
ber of individuals who carry several of the disease variants but do
not develop type 2 diabetes. Indeed, one can estimate from the
individual allele frequencies that 99% of the population carries
nine or more risk alleles, whereas only 8%–10% of the popula-
tion develops type 2 diabetes. Such low penetrance is consistent
with the mild effect of the risk variants, requiring the presence of
other factors, presumably environmental, for the development of
hyperglycemia. The mild effect may also be explained by the fact
that most of these variants are in noncoding regions of the gene,
where they may produce only subtle differences in regulation of
expression. This scenario contrasts sharply with that of Mende-
lian forms of diabetes, such as MODY, which are caused by rare
mutations in the coding sequence resulting in significant amino
acid substitutions or truncated proteins, leading to hyperglyce-
mia even in the absence of other diabetogenic exposures.
The third finding is that the loci identified to date appear to ex-
plain only a small proportion of the familial clustering of type 2 di-
abetes. Indeed, in the WTCCC study, the nine strongest loci to-
gether account for only 7% of the 30%–60% increase in the risk
of type 2 diabetes typically observed in siblings of type 2 diabe-
tes probands as compared to the general population (Zeggini
et al., 2007). If our current genetic models are correct (and this
remains an important question), this would suggest that the
loci identified to date are just the tip of the iceberg. In each
GWA scan, other loci showed significant associations with
type 2 diabetes but were not pursued because they were not
replicated across multiple studies. While some of these are cer-
tainly false positives, some of these are likely genuine effects that
need to be explored further.
At least four other hypotheses also need to be considered in
interpreting these studies. First, it is possible that our previous
estimates of the contribution of genetics to development of
type 2 diabetes may be exaggerated by our inability to assess
other factors in family and population studies, such as shared
environment. Indeed, there are environmental risk factors that
may not have been previously appreciated, and compared to
our robust approaches to genetic analysis, our techniques for
identifying environmental risk factors are still very primitive. Fur-
thermore, critical environmental exposures (e.g., maternal obe-
sity, intrauterine environment, nutritional composition, or differ-
ences in intestinal flora) may be subtle and begin as early as
intrauterine life, thus altering patterns of development and pro-
gramming metabolic responsiveness to environmental stimuli
during later life. Such concepts are supported by studies of
monozygotic twins, in which primary DNA sequence is identical,
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et al., 1999) and by the findings that low birth weight confers in-
creased risk for diabetes equal in magnitude to the effect of the
TCF7L2 polymorphism (Cauchi et al., 2006).
Second, our concepts about how genes interact with each
other and with the environment may be too simplistic. For exam-
ple, in a polygenic rodent model of type 2 diabetes created by
heterozygous inactivation of both the insulin receptor and IRS-
1, there is evidence of a very marked epistasis, such that neither
gene defect alone can produce diabetes in more than 10% of
mice, but when they occur together, more than 50% of animals
develop diabetes at young age (Figure 3A) (Bruning et al.,
Figure 3. Gene-Gene Interaction in the Etiology of Type 2 Diabetes
as Exemplified by Animal Models
(A) Epistasis between insulin receptor (IR) and insulin receptor substrate 1
(IRS1) gene targeting in the development of type 2 diabetes.
(B) Impact of genetic background on the development of type 2 diabetes in
mice with genetic insulin resistance.1997). Furthermore, appearance of ‘‘clinical’’ diabetes in this
and other rodent models can be markedly different depending
on the genetic background of the mouse, demonstrating other
important gene-gene interactions (Figure 3B) (Almind et al.,
2003).
Third, it is possible that the current models of genetics are
clouded by our underestimate of the role of epigenetics in dis-
ease. In rodent models that mimic low birth weight in humans
by food restriction or restriction of placental flow of pregnant
dams, it has now been clearly demonstrated that not only do
the low birth weight offspring have an increased risk of diabetes,
but this risk is passed on to the second generation, probably
through effects on intrauterine and early postnatal nutritional ef-
fects on genetic imprinting and/or epigenetic regulation of gene
expression or development (Sharif et al., 2007; Ozanne and Con-
stancia, 2007; Jimenez-Chillaron et al., 2006). Moreover, these
epigenetic marks, while resulting from early life exposures, can
actually progress during postnatal life and thus contribute to
age-dependent transcriptional repression of key metabolic
genes, as has recently been demonstrated for the b cell tran-
scription factor PDX1 (Park et al., 2008) and the insulin-sensitive
glucose transporter GLUT4 (Raychaudhuri et al., 2008, Woo and
Patti, 2008).
Finally, we need to consider the possibility that our model of
the genetics of type 2 diabetes with a moderate number of rela-
tively common polymorphisms causing disease, is wrong. If the
genetic component of type 2 diabetes is represented by uncom-
mon (<5% of the population), but highly penetrant, disease al-
leles, the GWA studies conducted to date would have been lim-
ited in their ability to find the disease genes since the current SNP
arrays capture only a small fraction of all the rare variants that are
estimated to exist in the human genome.
Insights into Pathogenesis from GWA Studies
The GWA association studies continue to open our eyes to the
broad nature of molecules that might contribute to the pathogen-
esis of type 2 diabetes. Clearly many of the genes identified in
both GWA and positional cloning studies would not be consid-
ered typical ‘‘candidate’’ genes. However, we do need to be cau-
tious about interpreting what these studies tell us about the
genes and tissues involved in the pathogenesis of type 2 diabe-
tes. It is especially important to keep in mind that most of the
observed associations are in large domains of strong linkage
disequilibrium in noncoding regions of the genome. These
association signals are usually named as if there are defects in
the closest specific gene, but many of these domains contain
multiple genes, and thus the ‘‘designated’’ type 2 diabetes
gene may or may not be the gene whose expression or function
is altered by the polymorphism. Also, in silico analyses predict
that up to 50% of conserved cis-acting elements in the human
genome are up to 1 Mb from target genes, sometimes in the
introns of neighboring genes (Vavouri et al., 2006). These
predictions have been confirmed by chIP-on-chIP experiments
(Carroll et al., 2005) and RACE data from the Encode project
(Birney et al., 2007). Thus, the true type 2 diabetes genes may
be placed at some distance from the association signals.
With these caveats in mind, it is interesting to note that several
of the genes placed in the proximity of GWA signals are ex-
pressed in b cells. This, together with the findings of associationCell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc. 195
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2007; Florez et al., 2006a; Sladek et al., 2007), has led some to
conclude that b cell defects have a more primal role in the etiol-
ogy of type 2 diabetes than insulin resistance or that changes in
muscle oxidative metabolic phenotypes are not genetic in origin.
However, this may not be necessarily the case. The focus of the
GWA studies on overt type 2 diabetes favored finding genes
marking a limitation of b cell function, since ultimately all forms
of diabetes could be viewed as having relative insulin deficiency.
The identification of variants predisposing to diabetes through
effects on insulin sensitivity will require other study designs,
such as ones based on association between insulin sensitivity
and genotype in the prediabetic state, i.e., before the onset of
overt hyperglycemia. Another factor clouding the discovery of
potential insulin resistance genes in GWA studies may be the
very strong environment-gene interactions for insulin resistance
with body weight, physical activity, and other factors, as com-
pared to the potentially purer manifestation of genetic control
on insulin secretion.
Implications of GWA Results for the Development
of New Diagnostics and Therapeutics for Type 2
Diabetes
One of the major promises of genetic research has been the
hope that this will lead us to new diagnostics and therapeutics
for disease. The new GWA findings could represent a significant
step in this direction, but it is still early to know. With regard to
prediction of disease, most of the single loci identified by GWA
mark only a 10%–20% increase in risk of disease, and even
the strongest single association, TCF7L2, represents only about
a doubling of disease risk in its homozygous state. Higher rela-
tive risks can be generated by combining multiple markers to-
gether. Indeed, about 97% of the population carry between 9
and 20 risk alleles at the 15 type 2 diabetes loci identified thus
far (Figure 4A). If we assume that these genetic effects are addi-
tive, the1.5% of the population who haveR20 risk alleles have
a 6-fold increase in the odds of developing type 2 diabetes as
compared to the 1.5% who carry %9 risk alleles (Figure 4B). In
terms of predictive value, this translates into an increment of
about 10 percentage points over the probability of type 2 diabe-
tes before the genetic test (from 7%—the prevalence of type 2
diabetes in the population—to 17%, Figure 4C). However, for
more common risk categories such as those defined by carrying
17 or 18 risk alleles, the increment over the prior probability is in
the order of only 3–5 percentage points (Figure 4C). The predic-
tive value of multiple positive markers could be higher if some of
the 15 type 2 diabetes genes interact with each other as one re-
cent report indicates (Cauchi et al., 2008b). However, other stud-
ies have not shown such synergistic effects. Thus, at present,
even a panel of multiple genes has uncertain usefulness in ge-
netic prediction, and it remains to be seen how this would com-
pare to traditional clinical markers of prediction, such as pres-
ence of obesity, family history, ethnic background, history of
low birth weight or gestational diabetes, etc.
With regard to therapeutic implications, these risk alleles do
point to a number of previously uninvestigated pathways that
might alter b cell function, insulin action, or metabolism. Even
for variants that have a small effect on type 2 diabetes risk, it is
conceivable that the activity of the cellular pathways in which196 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.these are placed can be modulated by drugs to a much larger ex-
tent than what is observed as the consequence of natural varia-
tion. On the other hand, some of these pathways, such as the
Wnt and cell-cycle pathways, are so central to normal cellular
Figure 4. Predictive Value of Multiple Genetic Markers for Type 2
Diabetes
(A) Number of risk alleles carried by individuals from the general population at
the 15 type 2 diabetes loci identified to date. Estimates are based on the risk
allele frequencies reported in Table 3 and assume independent segregation of
the 15 loci.
(B) Odds ratios of type 2 diabetes as a function of the number of risk alleles.
The average OR associated with each number of allele was estimated under
the assumption of a multiplicative (log-additive) model on the basis of the indi-
vidual ORs listed in Table 3 and the relative frequencies of the risk alleles in
each class.
(C) Probability of type 2 diabetes as a function of the number of risk alleles.
Estimates assume an average (pretest) probability of type 2 diabetes of 0.07
(indicated by the dashed line).
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difficult.
Looking Forward
Our knowledge of the genetics of type 2 diabetes has come
a long way since the days of a few candidate genes studied by
means of one or two haphazardly chosen restriction fragment
length polymorphisms. Yet, these new findings should be con-
sidered as a starting point rather than the arrival. There is little
doubt that additional type 2 diabetes loci and genes will be iden-
tified through follow-up of ‘‘hot spots’’ in the existing scans (Zeg-
gini et al., 2008) and GWA scans focused on certain ethnic
groups and specific clinical or pathophysiological phenotypes
of type 2 diabetes.
Also, the current analyses have only considered the effects of
individual SNPs in isolation from the effect of other genes or en-
vironmental factors. As the effect of these variants becomes in-
creasingly established, attention needs to be focused on gene-
gene and gene-environment interactions. Prospective cohorts
for which data are available on dietary exposures, physical activ-
ity, and other potential environmental modifiers will be needed to
accomplish this task.
Finally, it should be emphasized again that the current GWA
studies are based on the ‘‘common-disease/common-variant hy-
pothesis’’ holding that genetic predisposition to common disor-
ders isdeterminedbycommon genetic variantswithsmall ormod-
est effects (Reich and Lander, 2001). As discussed above, the
available genotyping arrays are not designed to investigate the al-
ternative ‘‘heterogeneity hypothesis’’ maintaining that susceptibil-
ity to common disorders results from a large number of rare vari-
ants, each having a relatively large effect (Pritchard and Cox,
2002). Identification of such rare variants, if they exist, will require
resequencing of the entire genome of type 2 diabetes cases and
controls. Fortunately, this previously insurmountable task is be-
coming increasingly realistic with the ongoing development of
new, powerful sequencing methods. Likewise, the contribution
of structural variants, such as copy-number variants, insertions,
deletions, and duplications, could also contribute to genetic sus-
ceptibility not explained by single nucleotide substitutions (Feuk
et al., 2006). With these additional pieces in hand, we would
have a complete view of the genetic architecture of type 2 diabe-
tes. We do not know how the final picture will look, but these initial
findings suggest that it will be different from anything we imagined.
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